Research and Development

Missing clinical trial data can harm patients and lead to needless costs for health systems, according to new research. A …

The FDA has accepted Pfizer’s novel arthritis pill tofacitinib for review, and could be on the US market next year. …

AstraZeneca and Novo Nordisk have linked up with a US biosciences firm in a bid to enhance their R&D operations. …

AstraZeneca has taken a major blow to its late stage pipeline, with one of its key cancer drugs now being …

 Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …

Vertex has named a new chief executive to succeed Matthew Emmens, who will retire early next year. He will be …

Kevin Sharer, Amgen’s chairman and chief executive, has announced his retirement next year, leading the way for Robert Bradway to …

Merck and Roche have started clinical trials to investigate combinations of their hepatitis C drugs. The first trial is designed …

Roche has made two new appointments in its corporate executive committee. Sophie Kornowski-Bonnet, currently general manager of Roche in France, …

Merck & Co chief executive Kenneth Frazier has expressed concern that European governments increasingly want to pay unrealistically low prices …

Pfizer’s chief executive and president Ian Read has been elected as the firm’s new chairman. Read succeeds George Lorch as …

Abbott has signed a new deal with inflammatory specialist Reata for its portfolio of early-stage compounds. Abbott and Reata Pharmaceuticals …

Lilly has elected Katherine Baicker as a new member of its board of directors, effective immediately. Baicker, 40, is Professor …

GlaxoSmithKline’s Tyverb has failed to help women with HER2 positive breast cancer increase their survival.  The TEACH study’s primary objective …

Each year the health service, the Department of Health and the UK pharmaceutical industry get an opportunity to say what …